Advertisement

NIH Primary and Secondary Prevention Research in Humans During 2012–2017

Published:October 25, 2018DOI:https://doi.org/10.1016/j.amepre.2018.08.006

      Introduction

      This paper provides the first detailed analysis of the NIH prevention research portfolio for primary and secondary prevention research in humans and related methods research.

      Methods

      The Office of Disease Prevention developed a taxonomy of 128 topics and applied it to 11,082 projects representing 91.7% of all new projects and 84.1% of all dollars used for new projects awarded using grant and cooperative agreement activity codes that supported research in fiscal years 2012–2017. Projects were coded in 2016–2018 and analyzed in 2018.

      Results

      Only 16.7% of projects and 22.6% of dollars were used for primary and secondary prevention research in humans or related methods research. Most of the leading risk factors for death and disability in the U.S. were selected as an outcome in <5% of the projects. Many more projects included an observational study, or an analysis of existing data, than a randomized intervention. These patterns were consistent over time.

      Conclusions

      The appropriate level of support for primary and secondary prevention research in humans from NIH will differ by field and stage of research. The estimates reported here may be overestimates, as credit was given for a project even if only a portion of that project addressed prevention research. Given that 74% of the variability in county-level life expectancy across the U.S. is explained by established risk factors, it seems appropriate to devote additional resources to developing and testing interventions to address those risk factors.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Preventive Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Calitz C
        • Pollack KM
        • Millard C
        • Yach D
        National Institutes of Health funding for behavioral interventions to prevent chronic diseases.
        Am J Prev Med. 2015; 48: 462-471
        • Murray DM
        • Cross WP
        • Simons-Morton D
        • et al.
        Enhancing the quality of prevention research supported by the National Institutes of Health.
        Am J Public Health. 2015; 105: 9-12
        • Mokdad AH
        • Ballestros K
        • Echko M
        • et al.
        The state of U.S. health, 1990–2016.
        JAMA. 2018; 319: 1444-1472
        • Villani J
        • Schully SD
        • Meyer P
        • et al.
        A machine learning approach to identify NIH-funded applied prevention research.
        Am J Prev Med. 2018; (In press 2018)
        • Wojcik BE
        • Stein CR
        • Devore RB
        • Hassell H
        The challenge of mapping between two medical coding systems.
        Mil Med. 2006; 171: 1128-1136
        • Dwyer-Lindgren L
        • Bertozzi-Villa A
        • Stubbs RW
        • et al.
        Inequalities in life expectancy among U.S. counties, 1980 to 2014: temporal trends and key drivers.
        JAMA Intern Med. 2017; 177: 1003-1011
        • Mokdad AH
        • Marks JS
        • Stroup DF
        • Gerberding JL
        Actual causes of death in the United States, 2000.
        JAMA. 2004; 291: 1238-1245
        • U.S. Preventive Task Force
        Sixth Annual Report to Congress on High-Priority Evidence Gaps for Clinical Preventive Services.
        (Published December 2017. Accessed September 20, 2018)